Selborne Biological Services

Executive Summary

Selborne Biological Services is a UK-based contract research organization (CRO) founded in 2018, headquartered in Cambridge, a global biotech hub. The company specializes in antibody-related services, including assay development, compound screening, and preclinical testing, supporting early-stage drug discovery for biotech and pharmaceutical clients. By leveraging Cambridge's scientific talent and network, Selborne positions itself as a nimble partner for companies seeking high-quality, specialized antibody services without the overhead of larger CROs. Its focus on early-stage development aligns with growing demand for outsourced research services as pharmaceutical companies increasingly rely on external partners to accelerate pipelines. The antibody CRO market is competitive, with players like Abcam, Bio-Rad, and Charles River, but Selborne differentiates through its boutique approach and strong local connections. The company's growth prospects hinge on expanding its client base and service offerings, potentially into adjacent modalities such as cell therapy or biologics characterization. Given its limited public profile and private status, near-term visibility is low, but the company's foundation in a thriving biotech ecosystem and its specialized expertise provide a solid platform for gradual expansion. Key risks include reliance on a small number of clients and the need for continuous innovation to stay relevant.

Upcoming Catalysts (preview)

• Q3 2026Major partnership with top-10 pharma for antibody screening panel40% success
• H1 2027Launch of CAR-T assay services to meet cell therapy demand30% success
• 2026Series A funding round to scale operations and sales50% success